Patients with hormone-refractory prostate cancer often have multiple bone metastases. The resulting bone pain is associated with reduced life quality, increased cost of therapy and impairment of overall survival. Trials with bone-targeting β-emitters have mostly showed an effect on alleviation of bone pain along with prolongation in survival, documented in only a limited number of patients. A randomized phase III trial (ALSYMPCA) using the α-emitter 223 RaCl 2 (Xofigo®) showed for the first time, a longer overall survival of 3.6 months in treated patients as a sign of an antitumor effect. The time to first skeletal-related events was also significantly longer in the therapy group compared with placebo. Because of the short range of α-emitter, the bone marrow toxicity of radium therapy is low, and so this radionuclide could also be a candidate for combination with chemotherapy. The elimination of 223 RaCl 2 is mainly through the gastrointestinal tract and side effects are mainly in this area. The procedure is similar to treatment with other bone-seeking agents and consists of six administrations of 50 kBq/kg bodyweight Xofigo®, repeated every 4 weeks. At present Xofigo® is only approved for hormone-refractory prostate cancer.
Introduction
Skeletal metastases occur in many patients with advanced prostate cancer. Resulting bone pain interferes with the patient's quality of life and requires effective treatment. Patients with bone metastases commonly endure severe bone pain and this symptom has the biggest impact on quality of life. Though the mechanisms involved in bone pain are poorly understood [Mantyh et al. 2002] , one of the important physical factors contributing to pain is thought to be osteolysis (bone breakdown) [Mundy, 2002] , especially with infiltration of the bone trabeculae and matrix by tumor osteolysis. Other factors include microfractures and stretching of the periosteum by tumor growth [Serafini, 1994] . Biochemical mechanisms of pain include the stimulation of nerve endings in the endosteum by a variety of chemical mediators, such as bradykinin, prostaglandin, histamine, interleukin and tumor necrosis factor produced by the osteolytic process [Nielsen et al. 1991; Rabbani et al. 1999 ].
The clinical course for most prostate cancer patients is not very aggressive, even with the presence of multiple skeletal metastases, and there are numerous treatment options currently available to them. Most of them live a long time with their disease and thus, are often suitable candidates for palliative treatment using bone-seeking radionuclide agents. Recent evidence also suggests that their use can result in a prolongation of survival time in patients with multiple bone metastases. In prostate cancer, the balance between resorption and mineralization is impaired, resulting in the overall formation of osteoblastic lesions [Keller et al. 2001 ], but the resorption by osteoclasts is not completely lost. Thus, increased systemic markers of both bone formation and resorption have been observed in patients with prostate cancer [Scher and Yagoda, 1987] . Patients with bone metastases from prostate cancer are the ideal candidates for therapy with bone-seeking radionuclide agents due to increased bone turnover by the osteoblastic process.
In the treatment of prostate cancer, hormone therapy [or androgen-deprivation therapy (ADT)] is essential. Unfortunately, as prostate cancer advances, it becomes hormone insensitive or castration resistant. At this stage, uncontrolled metastatic bone pain is one of the main symptoms and different strategies are employed to palliate this problem. First-line treatment is analgesic therapy as recommended by the three-step approach postulated by the World Health Organization. The first step for mild to moderate pain includes nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. aspirin, ibuprofen and naproxen). If the pain persists or increases, a weak opioid (e.g. codeine or naproxen) is added. For persistent or more severe pain, more potent or higher doses of strong opioids are used in step three (morphine, hydromorphone or fentanyl). The efficacy may be improved by concurrent administration of tricyclic antidepressive drugs or phenothiazine [World Health Organization, 1990] . However, strong opioids are associated with nausea, vomiting and constipation, occurring in more than 50% of patients using oral morphine, though these effects are usually treatable. Hallucination and confusion are unusual, but elderly patients may be at an increased risk for these side effects [Portenoy et al. 1994] .
Consequently, use of intravenous bisphosphonates to reduce bone loss and prevent skeletal complications has become essential in advanced prostate cancer. Bisphosphonates represent analogues of endogenous pyrophosphates [Lipton, 1997] and induce apoptosis of osteoclasts [Shipman et al. 1997 ]. The differentiation of the osteoclastic precursor to mature osteoclasts is also inhibited by bisphosphonates [Lowik et al. 1988] . Earlier generations of bisphosphonates (etidronate and clodronate) showed only transient and nonstatistically significant pain relief in placebo-controlled studies [Ernst et al. 2003 ]. Pamidronate and zoledronic acid are second-and third-generation nitrogen-containing bisphosphonate formulations approved for use in bone metastases [Paes and Serafini, 2010] . They have both demonstrated the ability to reduce skeletal complications and morbidity in patients with cancer [Berenson et al. 2001] . Reports have suggested that RANKL inhibitor, denosumab, significantly reduces the risk of developing first symptomatic skeletal-related events compared with zoledronic acid (20.7 versus 17.1 months) [Smith et al. 2015; Todenhöfer et al. 2015] .
Extensive clinical evidence has established bisphosphonates as useful agents for treating bone metastasis associated with breast cancer [Powles et al. 2002] . There is less evidence demonstrating the therapeutic efficacy of bisphosphonates in metastatic prostate cancer, with some trials suggesting no effects from treatment [Mason et al. 2007] and others indicating only a reduction in bone pain [Heidenreich et al. 2002; Weinfurt et al. 2006 ]. There are also some new nonbisphosphonate candidates for the treatment of bone resorption. Clohisy and colleagues and Morony and colleagues identified osteoprotegerin and its ligands as naturally occurring proteins that inhibit and stimulate osteoclast formation [Clohisy et al. 2000; Morony et al. 2001] . In animal models, osteoprotegerin can inhibit bone lesions caused by a murine adenocarcinoma cell line (C26-DCT). Parathyroid hormone-related proteins (PTHrP) may play an important role in the establishment of osteolytic lesions [Guise et al. 1996; 2002] , and their antagonists could be a candidate for therapy. Other interesting agents include endothelin-receptor antagonists, for example, atrasentan. In a placebo-controlled trial, 288 patients with bone metastases from prostate cancer were treated with 2.5 or 10 mg of atrasentan compared with placebo. Atrasentan (10 mg) not only reduces the rise in bone alkaline phosphatase significantly, that is a marker of bone formation, but also reduces the markers of bone resorption compared with placebo [Nelson et al. 2003 ].
Indications for radiotherapy in bone metastases include pain, risk for pathological fracture and neurological complications arising from spinal cord compression, nerve root pain, or cranial involvement [Janjan, 2006] . About 20% of all radiotherapies are performed for painful bone metastases [Agarawal et al. 2006 ]. Meta-analysis data have established that more than 40% of treated patients can expect at least 50% pain relief, and fewer than 30% can expect complete pain relief at 1 month [Saarto et al. 2002] . Numerous external beam radiotherapy regimes may be employed in the management of bone pain, included fractionated schedules and singlefraction regimes [Paes and Serafini, 2010] .
Single-fraction therapy is perhaps the most useful form of radiotherapy because of its relative convenience for the patient and radiotherapy unit, as well as its lower cost. This treatment can be used for patients with metastases on nonweight-bearing bones, such as the clavicle and the ribs, or on weight-bearing bones in the absence of large lytic lesions, as well as in patients with terminal disease. The recommended dose is 6-8 Gy [Steenland et al. 1999 ]. Multiple-fraction radiotherapy can be used in patients with lytic lesions in weightbearing bones or vertebral metastases causing spinal cord or nerve root compression and in the post-surgical treatment of pathological fractures. This strategy allows higher doses of radiation to be administered, leading to a greater reduction in tumor size and longer delay in tumor growth. Commonly used regimes include 30 Gy in ten fractions or 20 Gy in five fractions [Steenland et al. 1999] . Controversy exists regarding whether single-or multiple-fraction radiotherapy is superior [Gaze et al. 1997 ] with some trials indicating that single-fraction therapy could be as effective (both in pain relief and duration of response) as multiple-fraction therapy [Nielsen et al. 1998; Uppelschoten et al. 1995] . Some trials have demonstrated that higher doses of radiation were more effective, particularly for patients with a relatively good prognosis [Arcangeli et al. 1998; Ratanatharathorn et al. 1999] . Others revealed no differences between the two schedules [Kuban et al. 1989 ].
Radium-223 dichloride
Xofigo® (Bayer Pharma, Berlin, Germany) is a solution of Radium-223 dichloride ( 223 RaCl 2 ) for intravenous administration in patients with castration-resistant prostate cancer (CRPC) and metastatic bone pain. As an alkaline earth metal, 223 RaCl 2 mimics the calcium uptake in whole bone and is termed a volume seeker [Liepe, 2009] . In contrast, the radioactive-labelled bisphosphonates are termed surface seekers [Liepe and Kotzerke, 2011] . The α-emitters have a high linear energy transfer and result in a high incidence of DNA double-strand breaks, which lead to a strong tumor-cell-killing effect [Henriksen et al. 2002] . The short track length of 2-10 cell diameters minimizes the cell-damage effect in surrounding healthy tissue, but also reduces the tumor-killing effect to a very short distance in the bone.
Pharmacokinetics and dosimetry. 223 RaCl 2 has a physical half-life of 11.4 days. It undergoes a sixstep decay to produce 207 lead via a series of α-, βand γ-emitting daughters (94% as α-emitter, 4% as β-emitter and 2% as γ-emission) [Bruland et al. 2006 ]. Pharmacokinetic studies in 10 patients with applied activities from 50 to 200 kBq of 223 RaCl 2 documented a fast clearance from the vascular compartment, with only 14% (range 9-34%), 2% (range 1.3-3.9%), and 0.5% (range 0.4-1.0%) remaining in the plasma immediately, at 4 hours and 24 hours after administration, respectively [Carrasquillo et al. 2013] . In contrast to radiolabeled diphosphonates or 89 strontium ( 89 Sr), the excretion is mainly through the intestine (13%ID) and a significantly lower percentage via urine (2%ID). Most of the administered activity was taken up rapidly into bone with greater than 60% of administered activity incorporated by 4 hours [Chittenden et al. 2015 ].
The extremely low range of α-emitters led to a heterogeneous distribution of cellular-absorbed dose, which is strongly dependent on the distance from the fixed 223 RaCl 2 in the normal bone structures to the bone metastases. The main radiation to the bone marrow comes from the fixed 223 RaCl 2 in the trabecular system that is adjacent to the red marrow cells. Thus, the uptake in cortical bone does not contribute significantly to marrow toxicity. Considering this point, the trabecular model was used for calculation of the red marrowabsorbed dose in all patients receiving this therapy. This model assumes two scenarios: that the radiopharmaceutical is in the bone marrow matrix that leads to a lower radiation-absorbed dose; or that the localization is in the endosteal layer that in turn leads to a significantly higher dose. Results from trabecular models differ markedly from standard absorbed-fraction methods. Results suggest that increasing the amount of radioactivity may not substantially increase the risk of marrow toxicity, in contrast to the absorbed-fraction method of dose calculation for a β-emitter [Hobbs et al. 2012] . After a treatment schedule of six administrations with 0.05 MBq/kg bodyweight of 223 RaCl 2 , the absorbed alpha dose to the bone endosteal cells is about 16 Gy and the corresponding absorbed dose to red bone marrow is approximately 1.5 Gy [Lassmann and Nosske, 2013] . Dosimetric studies of bone metastases showed an absorbed dose of 0.7 Gy (range 0.2-1.9 Gy) after first administration of 50 kBq/kg bodyweight of 223 RaCl 2 . It is to be noted that when using 223 RaCl 2 , what could be more important is the relative biological effectiveness (RBE) of α-emitters (RBE = 5), which is approximately 899 mGy/MBq (range 340-2450 mGy/MBq). Thus the calculated dose of relative biological effectiveness (D RBE ) for six cycles of 223 RaCl 2 is approximately 18.9 Gy, which is comparable with D RBE of 10.4 Gy when using samarium-153-EDTMP ( 153Sm EDTMP) or 34.0 Gy using 89 SrCl 2 [Pacilio et al. 2016] .
Clinical studies. Authors of three phase I studies investigated the biodistribution, dosimetry and safety of 223 RaCl 2 in humans [Nilsson et al. 2004 [Nilsson et al. , 2005 Nielsen et al. 2010] . The main goal of the ATI-BC-1 study was to estimate the safety and tolerability with dose escalation of 223 RaCl 2 in breast and prostate cancer patients. Patients (n = 31) were given a single administration of 46, 93, 163, 213 or 250 kBq/kg bodyweight of 223 RaCl 2 . Even in the high-activity group, no dose-limiting hematologic toxicity was documented. Thrombocytopenia was minor with only grade I toxicity noted, but grade III neutropenia and leukopenia occurred in two and three patients, respectively, with a nadir between the second and fourth week. Nausea and vomiting were more frequently observed in the highest-dosage group induced by nonspecific uptake or excretion of 223 RaCl 2 in the gut. Rapid blood clearance was documented by a decrease of blood radioactivity from 12% of the administered dose (%ID: percentage injected dose) at 10 min, to 6%ID at 1 hour and to <1%ID at 24 hours in a time period of 48 hours [Nilsson et al. 2005] . The main goal of the two phase II studies was to investigate the possibility of repeated administrations (BC1-02 and BC1-04). In BC1-02, patients with CRPC were assigned to four injections of 50 kBq/kg 223 RaCl 2 (n = 33) versus placebo (n = 31). Primary endpoints were change in alkaline phosphate (ALP) level and time to first skeletal-related event (SRE). Median relative change in bone ALP from baseline was 66% decrease after 223 RaCl 2 versus only 9% after placebo 4 weeks after last administration. In addition, a prolonged overall survival (OS) was observed in the 223 RaCl 2 group (65.3 weeks) versus placebo (46.4 weeks) (p = 0.066) [Nilsson et al. 2007 ]. Parker and colleagues used dose escalation with three injections of 25 kBq/kg (n = 41), 50 kBq/kg (n = 39), or 80 kBq/kg (n = 42) in 122 patients with CRPC. Slightly extended survival was observed in the groups receiving 50 and 80 kBq/kg, but not in patients receiving 25 kBq/kg of 223 RaCl 2 . [Parker et al. 2013a ]. Nilsson and colleagues investigated the effect of single dose of 5, 25, 50, or 100 kBq/ kg in 100 CRPC patients. Pain relief in all patients was documented, but a significant decrease of ALP after 4 weeks was noted only with 50 or 100 kBq/kg of 223 RaCl 2 [Nilsson et al. 2012] .
In summary, the phase I and II studies with more than 300 patients demonstrated that multiple administrations with doses up to 100 kBq/kg, or single administration up to 250 kBq/kg of 223 RaCl 2 was well tolerated. Patients showed pain relief, extended survival and decrease of biochemical markers [ALP and prostate-specific antigen (PSA)] within 12 months after therapy.
ALSYMPCA trial. In this double-blind randomized phase III study (2008-2011) 921 CRPC patients were enrolled. Inclusion criteria included bone pain and at least two bone metastases, without metastases outside the skeleton [Parker et al. 2013a; Sartor et al. 2014 ]. The study design consisted of six administrations of 50 kBq/kg 223 RaCl 2 with an interval of 4 weeks between injections. Patients were stratified by the pretherapeutic ALP level (<220 U/l versus ⩾220 U/l) and pretherapeutic bisphosphonate or docetaxel therapy. They were randomly assigned in a 2:1 ratio to the radium or placebo group. That is the first study using bone-seeking agents in bone metastases that used the OS as the primary endpoint, and a sufficient number of treated patients for statistical evaluation. Secondary endpoints were time to first SRE, time to PSA or ALP progress, decrease of ALP after therapy, patient safety using the rate of side effects and the influence on quality of life. In summary, 614 patients in the 223 RaCl 2 group and 307 patients in the placebo group were evaluated. In the therapy group only 63% of patients were given six administrations of 50 kBq/kg 223 RaCl 2 , and in the placebo group 47% had six administrations of saline injection.
In the ALSYMPCA study, the 223 RaCl 2 arm had an OS of 14.9 months compared with the placebo arm that had 11.3 months (Figure 1) . The authors concluded that 223 RaCl 2 could extend the OS by 3.6 months in CRPC patients. Patients with widespread bone metastases (ALP level ⩾ 220 U/l) had a more significant prolongation in OS compared with patients having more limited bone metastases (ALP level < 220 U/l). The pretherapeutic opioid, bisphosphonate or docetaxel therapy didn't have any influence on the therapeutic effect or rate of side effects, except for a slightly higher rate of thrombocytopenia after docetaxel pretherapy [Hoskin et al. 2014 ]. Significant pain relief was documented up to16 weeks after therapy [Nilsson et al. 2013] . In a single case, a decrease in bone turnover was noted on the follow-up scan 6 months after therapy (Figure 2) .
Radiation protection.
Comparing α-emitters with β-radionuclides, problems with radiation exposure for staff are limited. However, there are some problems with the daughters of 223 RaCl 2 . The second step of the decay produces 219 radon with a physical T ½ of 3.96 seconds that is exhaled by patients; there is a fast decrease in the blood activity within the first hour itself. This leads to a limited radiation exposure of <0.01 mSv, mainly through personal communication. To reduce the radiation exposure from low activity of 219 radon in the exhaled air the staff should keep certain distance from patients within the first hour post administration. The last decay from 207 thallium to 207 lead emits beta rays, which leads to a radiation-exposure dose rate of 1.8 mSv/h, using 6 MBq of 223 RaCl 2 on the surface of an unshielded syringe (Federal Office for Radiation Protection, 2015) . Use of 5 mm perspex shielding around the syringe can limit this radiation exposure significantly. In contrast, the deep-dose equivalent is only 0.3 µSv/h per MBq of 223 RaCl 2 , which is equivalent to a dose rate of 0.03 µsv/minute [Rimpler, 2015] .
The multicenter RHAPSODY study [Wanke et al. 2014 ] was designed to estimate the radiation dose to relatives and caregivers during outpatient therapy with 223 RaCl 2 in Germany. In this study, the ambient external radiation exposure was measured using standard dose-rate meters at a distance of 1 and 2 m. Excreted Ra-223 was measured in saliva using swabs, and in sweat using skin patches. Wipe tests were taken in the patients' homes in the restroom and kitchen to identify significant contamination. Preliminary results showed measurable amounts of 223 RaCl 2 in the range of 10-100 Bq/g in saliva. The skin patch measurements indicated perspiration activity of about 0.02-0.5 Bq/cm 2 in the first 24 hours post injection (PI). Contamination in restrooms and kitchens was found to be less than 0.05 Bq/cm 2 . However, significant amounts of 219 Radon were exhaled immediately after injection. Concentrations of more than 2 kBq/l of 219 Radon were measured in exhaled air. The authors concluded that the external exposure from the patients can be neglected and it is unlikely that Ra-223 excreted in sweat and saliva or contaminations in the patients' homes would lead to effective doses exceeding 1 mSv per year for relatives [Liepe, 2015] .
Short-term side effects. 223 RaCl 2 in bone pain palliation is well tolerated with a low rate of side effects, especially bone marrow toxicity. The main side effects reported by patients are gastrointestinal, due to the intestinal route of excretion. The most common complaints were nausea and diarrhea in 36% and 25% of patients, respectively. Other symptoms include fatigue (26%), loss of weight (12%) and peripheral edema (13%). The 'flare' phenomenon was described in 50% of treated patients. In contrast to β-emitters, marrow suppression is most commonly manifested as anemia, which was observed in 31% of patients. Thrombocytopenia (12%) and neutropenia (5%) were less commonly observed [Parker et al. 2013b; Sartor et al. 2014] . Interestingly, the rates of side effects in the ALSYMPCA study were similar in the placebo-and 223 RaCl 2 -treated groups.
The subgroup analysis in patients with or without previous docetaxel therapy documented a higher incidence of grade 3-4 thrombocytopenia in the patient subgroup who received 223 RaCl 2 after previous docetaxel therapy, compared with patients receiving placebo and previous docetaxel (9% of 347 patients versus 3% of 171 patients). In contrast, in the 223 RaCl 2 and placebo groups without previous docetaxel, a similar rate of grade 3-4 thrombocytopenia (3% of 253 patients versus 1% of 130 patients) was observed [Hoskin et al. 2014 ].
Long-term side effects. There is a long latency time (15-33 years) from radiation exposure to tumor induction [Nekolla et al. 2010 ]. Hence, radiation-induced tumorigenesis is not expected to be a problem for CRPC patients with bone metastases in light of the reduced life expectancy in these patients.
Actual data concerning long-term side effects using 223 RaCl 2 are not available. However, 223 RaCl 2 is an α-emitter and a calcium analogue, comparable with the bone-seeking agent 224 RaCl 2 . Between the 1970s and 1990s, many patients with ankylosing spondylitis were treated using 224 RaCl 2 [Liepe, 2015] . In 1985, Wick and colleagues published data concerning long-time side effects in 1568 patients with 224 RaCl 2 therapy and compared these with a control group (ankylosing spondylitis patients without 224 RaCl 2 therapy) [Wick et al. 1985] . They couldn't find any differences in mortality or incidence of leukemia or bone tumors between the treated group and controls. However, the same group published another study with different results, reporting 19 cases of leukemia in the exposed group (versus 6.8 cases expected, p < 0.001) compared with 12 cases of leukemia in the control group (versus 7.5 cases expected). Further subclassification of these leukemia cases demonstrated a high incidence of myeloid leukemia in the exposed group (11 cases observed versus 2.9 cases expected, p < 0.001), with a high excess of acute myeloid leukemia (7 cases observed versus 1.8 cases expected, p = 0.003); whereas in the controls the observed cases were within the expected range (4 myeloid leukemia versus 3.1 cases expected) [Wick et al. 2008 ]. Nekolla and colleagues found a slight increase of tumor incidence in patients treated with 224 RaCl 2 . These cases consisted of mainly young patients (<21 years) with high levels of administered activity, up to 140 MBq [Nekolla et al. 2010] .
Current opinion
The treatment of bone metastases with 223 RaCl 2 is an interesting new approach in the treatment of CRPC patients with bone metastases and shows an extended OS for the first time. However, in contrast to the treatment using β-emitters, the data were limited to one large trial (ALSYMPCA). Metastatic bone pain has been treated with β-emitters since the 1940s, and a significant volume of data exists to support the effectiveness of this modality. More recent reports have suggested that a combination of chemotherapy and bone pain palliation, or β-emitters following two or three cycles of induction chemotherapy (ketoconazole plus doxorubicin alternating with estramustine plus vinblastine) improved the treatment and palliative efficacy. In another study, clinically stable patients with CRPC were randomized to receive weekly doxorubicin with or without 89 Sr for 6 weeks. The estimated median survival for patients receiving 89 Sr was 27.7 months, compared with 16.8 months for patients who received doxorubicin alone (p = 0.0014) [Tu et al. 2001] . A combination of 89 Sr and cisplatin leads to a significantly higher pain relief (91%) compared with 89 Sr alone (63%; p < 0.01) [Sciuto et al. 2002] . Additionally, patients with CRPC administered chemotherapy (estramustine or mitoxantrone plus prednisone) within 1 month of 153Sm EDTMP therapy demonstrated superior clinical response rates compared with patients who received 153Sm EDTMP alone (87.5% versus 53.3%; p = 0.0388). A significantly superior PSA response (p = 0.0235) and median survival time (30 versus 11 months; p = 0.008) were also observed in these patients who were treated with combination therapy [Ricci et al. 2007 ]. Further promising data have also been reported with combinations of docetaxel and 153Sm EDTMP [Fizazi et al. 2009 ]. Trials with other radionuclides are expected to demonstrate similar effects.
An α-emitter (such as 223 RaCl 2 ), with short-range of emission which leads to a bone marrow-sparing effect, in combination with chemotherapy would be a potentially valuable modality to increase the survival of patients with bone metastases and would likely demonstrate reduced bone marrow toxicity compared with current therapies.
Other interesting therapeutic approaches include the combination of systemic radionuclide therapy with bisphosphonates and local-field externalbeam radiation. Potential synergistic effects of a radionuclide-bisphosphonate combination have been noted in patients earlier [Soerdjbalie-Maikoe et al. 2002] , and systemic radionuclide therapy as an adjuvant to local-field external-beam radiation has demonstrated good therapeutic results. New therapeutic options in the treatment of metastatic bone pain, such as endothelin-1 antagonists [Fizazi et al. 2003 ], osteoprotegerin, transforming growth factor (TGF)-β, monoclonal antibodies [Kakonen et al. 2002] or fibroplast growth-factor (FGF) inhibitors [Nakamura et al. 1995] offer competition to radionuclide therapies, although synergistic effects are conceivable (particularly with FGF, as evidence has demonstrated radiosensitization following FGF inhibition) and warrant evaluation.
Finally, patients with bone metastases are mainly treated in the advanced stages of disease with severe pain symptoms and high levels of analgesic intake. Consideration should be given to treating patients in the early stages of metastatic cancer. Kraeber-Bodere and colleagues demonstrated a significantly better efficacy of 89 Sr in systemic radionuclide therapy for pain relief (p = 0.005), a reduced need for analgesics (p = 0.018) and a longer duration of response (p < 0.0035) in patients with moderate bone involvement compared with more advanced cases [Kraeber-Bodere et al. 2000 ]. Other investigators have demonstrated similar incremental improvements with early intervention and treatment. radiopharmaceutical therapy. Phys Med Biol 57: 3207-3222. Hoskin, P., Sartor, O., O'Sullivan, J., Johannessen, D., Helle, S., Logue, J. et al. (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase III ALSYMPCA trial. Lancet Oncol 15: 1397 -1406 . Janjan, N. (2006 Palliation and supportive care in radiation medicine. Hematol Oncol Clin North Am 20: 187-211.
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